

# CURRICULUM VITAE: *Dr Murali Varma*

## **QUALIFICATIONS**

FRCPath (UK); USA Board of Pathology certification: Cytology and AP/CP; MD Pathology (India); MBBS (India).

## **CURRENT POSITION**

Consultant Histopathologist (since 1999): University Hospital of Wales, Cardiff, Wales, UK.

## **DETAILS OF PATHOLOGY EXPERIENCE**

- Residency (AP/CP) and Fellowship (Cytology): Henry Ford Hospital, Detroit, USA (1995-99).
- Senior House Officer, Registrar, Senior Registrar (histopathology): Royal Victoria Hospital, Belfast, UK (1987-92 & 1993-5).
- Resident and Senior Resident: PGIMER, Chandigarh, India (1983-86).

## **POSITIONS OF RESPONSIBILITY (Selected)**

- Chair, British Association of Urological Pathologists (BAUP) 2017-2020.
- Chair, Working Group, ISUP consensus conference on prostate cancer grading, 2019.

## **NATIONAL/INTERNATIONAL GUIDELINES (Selected)**

1. *WHO classification of tumours 2022: Urinary and male genital tumors*. Co-author 2 chapters.
2. *Royal College of Pathologists dataset for tumours of urinary tract, 2022*. Lead author.
3. *International Collaboration on Cancer Reporting datasets for prostate cancer, 2017*. Co-author.

## **BOOK CHAPTERS**

1. Varma M et al. *Equivocal prostate needle biopsies*. In *Challenges in prostate cancer*. Blackwell publishing. 2006.
2. Varma M, et al. *Pathology of prostate cancer*. In *ABC of prostate cancer*. Wiley-Blackwell. 2012.

## **SYMPOSIUMS GUEST EDITED**

1. Macroscopy under the microscope. *J Clin Pathol* 2024.
2. The value and clinical utility of information in Pathology reports. *J Clin Pathol* 2022.
3. Uropathology reporting: communication and clinical utility of data. *Diagnostic Histopathol* 2021.

## **PUBLICATIONS (Selected main author)**

1. Varma M et al. *Personalised histopathology reporting for personalised medicine*. *Virchows Arch* 2020;477:323-5.
2. Varma M, et al. *Clinical utility of histopathology data: urological cancers*. *J Clin Pathol* 2022;75:506-13.
3. Varma M, et al. *Macroscopic examination of pathology specimens: a critical reappraisal*. *J Clin Pathol* 2024;77:164-168.
4. Varma M et al. *Histological sampling protocols for transurethral resection of prostate specimens need reappraisal*. *Histopathology* 2024;85:746-747.
5. Varma M, et al. *Head-to-head: how many categories for grading urothelial carcinoma?* *Histopathology* 2024;84:421-428.
6. Varma M. *An update on atypical large glandular proliferations of the prostate*. *Diagn Histopathol* 2023;29:283-293.
7. Varma M. *Intraductal Carcinoma of the Prostate: guide for the practicing pathologist*. *Adv Anat Pathol* 2021;28:276-287.
8. Esserman L, et al. *Should we rename indolent cancers?* *BMJ* 2019;364:k4699.
9. Varma M et al. *Low-risk cancer: recalibrate rather than just rename*. *BMJ* 2018;363:k4211.
10. Varma M et al. *Potential sources of overdiagnosis in histopathology*. *BMJ*. 2012;24;345:e5722.

## **COURSES ORGANISED/CONDUCTED (Selected)**

1. *BAUP monthly urological pathology webinars*. Since September 2023.
2. *Personalised pathology reporting for personalised medicine*. 2-day virtual meeting. 2022.
3. *The BAUP Prostate Pathology Course: 2006-24 (annual)*.
4. *The BAUP Bladder Pathology Course: 2008-24 (annual)*.
5. *Pathology for surgeons*. 2018.

## **LECTURES AND PRESENTATIONS (Selected)**

1. USCAP annual meeting, Baltimore, USA, 2024. Noninvasive bladder lesions: Terminology issues and controversies.
2. BAUP annual meeting, London, UK, 2019. *Role of the pathologist in MDT meetings: A critical re-appraisal*.
3. Prostate cancer multidisciplinary workshop, Manchester 2019: *Pathology in the patient pathway*.
4. Breast cancer MDT meeting, Tromso, Norway 2018. *Pathologists and Clinicians: Bridging the communication gap*.
5. Swedish Society of Pathology, Uppsala, Sweden 2016: *Grading urological cancers*.
6. European Congress of Pathology, Bilbao, Spain 2018: *Understanding Gleason Grading*.
7. World Congress IAP, Cape Town, South Africa 2012: *Prostate biopsies processing and immunochemistry*.
8. Belgian Society of Pathology, Ghent, Belgium 2015: *Gleason grading: An update and interactive quiz*.
9. Urocancer MDT Meeting, Bergen, Norway 2018: *From Gleason to Grade Groups: How did we get there?*
10. BDIAP annual meeting, Maastricht, The Netherlands 2018: *Intraductal carcinoma of the prostate gland*.